Clinical, chemical, and fibrosis parameters in treated and untreated groups of rats
| Sham 16 w 1–6 | BDO w 1–6 | BDO 8 w 1–6 | BDO 16 w 1–6 | BDO 16 w 4–6 | |
|---|---|---|---|---|---|
| Data are median (25th/75th percentiles). | |||||
| Sham 16 w 1–6, sham operation and PTX at 16 mg/kg/day for six weeks; BDO w 1–6, bile duct occlusion alone for six weeks; BDO 8 w 1–6, bile duct occlusion and PTX at 8 mg/kg/day for six weeks; BDO 16 w 1–6, bile duct occlusion and PTX at 16 mg/kg/d for six weeks; BDO 16 w 4–6, bile duct occlusion for six weeks and PTX at 16 mg/kg/day from week 4 to week 6. | |||||
| BW, body weight; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GT, gamma glutamyltransferase; ALP, alkaline phosphatase; Bili, total bilirubin; Crea, creatinine. | |||||
| Significances were calculated using the Mann Whitney rank sum test: *p<0.05, **p<0.01 versus untreated group (BDO alone). | |||||
| AST (U/I) | 82.5 (50/95) | 93.5 (81/154) | 127* (108/162) | 135* (106/161) | 98.5 (93/135) |
| ALT (UI) | 19.0 (17/22) | 25.5 (20/30) | 26.0 (22/35) | 26.5 (23/33) | 26.0 (21/31) |
| γ-GT (U/I) | 2.00 (1.0/2.0) | 19.5 (18/23) | 18.0 (15/24) | 20.0 (18/26) | 16.5 (16/23) |
| ALP (U/I) | 77.5 (57/89) | 275 (247/330) | 317 (272/355) | 262 (243/305) | 312 (263/370) |
| Bili (μmol/l) | 6.15 (5.7/6.8) | 167 (138/199) | 171 (162/192) | 165 (145/180) | 153 (128/178) |
| Crea (μmol/l) | 42.0 (41/47) | 32.0 (32/36) | 34.0 (32/38) | 32.0 (31/35) | 40.0** (35/41) |
| Increase BW (%) | 27.1 (6.8) | 27.3 (11.5) | 22.6 (8.9) | 18.6* (9.5) | 25.3 (10.3) |
| Liver weight (g) | 8.63 (0.87) | 25.1 (2.6) | 23.3 (3.3) | 21.4** (2.1) | 24.9 (3.4) |
| Spleen weight (g) | 0.63 (0.06) | 1.83 (0.36) | 1.60* (0.48) | 1.38** (0.28) | 1.81 (0.48) |